| scholarly article | Q13442814 |
| P50 | author | Alan Jardine | Q42650581 |
| P2093 | author name string | A Hartmann | |
| A G Olsson | |||
| E Cole | |||
| H Holdaas | |||
| B Maes | |||
| P Ambühl | |||
| S Madsen | |||
| T R Pedersen | |||
| H-H Neumayer | |||
| G Nyberg | |||
| B Fellström | |||
| C Grönhagen-Riska | |||
| B Staffler | |||
| Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators | |||
| P2860 | cites work | Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation | Q36163801 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 2929-2936 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study | |
| P478 | volume | 5 |
| Q28301815 | 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q44901282 | Assessment of nonimmunologic factors in kidney transplant recipients according to Kidney Disease Improving Global Outcomes |
| Q36377149 | Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients |
| Q51591010 | Associations of Selected Cytokines Levels in Organ Transplant Recipients Without and With Malignant Skin Neoplasms. |
| Q42637253 | Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients |
| Q35030586 | Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis |
| Q80166860 | Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease |
| Q35463999 | CKD-MBD after kidney transplantation |
| Q39968149 | Cardiac Events After Kidney Transplantation According to Pretransplantation Coronary Artery Disease and Coronary Revascularization Status |
| Q36993722 | Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets |
| Q83854398 | Cardioprotective role of statins in chronic kidney disease: do we have the answer? |
| Q38177489 | Cardiovascular complications after transplantation: treatment options in solid organ recipients |
| Q38235860 | Cardiovascular morbidity and mortality after kidney transplantation |
| Q36662065 | Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited |
| Q53856889 | Cause of Death With Graft Function Among Renal Transplant Recipients in an Integrated Healthcare System |
| Q35476894 | Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation |
| Q92919658 | Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses |
| Q24642788 | Chronic kidney disease mineral and bone disorder in children |
| Q34402661 | Chronic kidney disease: mineral and bone disorder in children |
| Q39094213 | Clinical significance of 'cardiometabolic memory': a systematic review of randomized controlled trials |
| Q33807224 | Correlates of the severity of coronary atherosclerosis in long-term kidney transplant patients. |
| Q34368831 | Death with functioning kidney transplant: an obituarial analysis |
| Q36641460 | Developing a tool for noninvasive monitoring of renal allografts. |
| Q27012546 | Diabetic kidney disease: a report from an ADA Consensus Conference |
| Q27024676 | Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies |
| Q44120234 | Differences in cardiac structure assessed by echocardiography between renal transplant recipients and chronic kidney disease patients. |
| Q93227561 | Disorders of Serum Polyunsaturated Fatty Acids in Renal Transplant Patients |
| Q57750401 | Do patients with CKD benefit from lipid-lowering therapy? |
| Q37226086 | Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes? |
| Q80166833 | Does pravastatin safely and effectively improve lipid profiles in children who have received a kidney transplant? |
| Q26851294 | Dyslipidemia and its therapeutic challenges in renal transplantation |
| Q37565707 | Dyslipidemia following kidney transplantation: diagnosis and treatment |
| Q37447007 | Dyslipidemia in patients with chronic and end-stage kidney disease |
| Q39045120 | Dyslipidemia in patients with chronic kidney disease |
| Q37683776 | Early origins of cardiovascular disease in pediatric chronic kidney disease |
| Q33871260 | Early statin use is an independent predictor of long-term graft survival |
| Q92854055 | Effect of Fluvastatin on Cardiovascular Complications in Kidney Transplant Patients: A Systemic Review and Meta-analysis |
| Q28551509 | Effect of Statins on the Progression of Coronary Calcification in Kidney Transplant Recipients |
| Q34667281 | Effect of left atrial and ventricular abnormalities on renal transplant recipient outcome-a single-center study |
| Q31120569 | Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study |
| Q35622529 | Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial |
| Q37873794 | Evidence-based statin prescription for cardiovascular protection in renal impairment. |
| Q57750555 | Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients |
| Q24200984 | HMG CoA reductase inhibitors (statins) for kidney transplant recipients |
| Q24241098 | HMG CoA reductase inhibitors (statins) for kidney transplant recipients |
| Q24241472 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis |
| Q33548525 | HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival |
| Q36172191 | Implementation of guidelines for metabolic syndrome control in kidney transplant recipients: results at a single center |
| Q37258914 | Inflammation in renal transplantation |
| Q57956739 | Inflammation-associated graft loss in renal transplant recipients |
| Q36259538 | Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients |
| Q30245459 | Interpretation of the evidence for the efficacy and safety of statin therapy |
| Q38217776 | Is there sufficient enhancement of the reduction in CVD rates after a decade of statin therapy to justify continuation? |
| Q56908136 | La transplantation des patients à risque cardio-vasculaire |
| Q27024982 | Lipid abnormalities in kidney disease and management strategies |
| Q42688659 | Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. |
| Q41690923 | Lipid lowering in renal disease |
| Q58561315 | Lipid management in patients with chronic kidney disease |
| Q38181583 | Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure? |
| Q38011919 | Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe? |
| Q36025075 | Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). |
| Q37089454 | Management of cardiovascular disease in renal transplant recipients |
| Q38878462 | Meta-analysis of statins in chronic kidney disease: who benefits? |
| Q36583335 | Model comparisons of competing risk and recurrent events for graft failure in renal transplant recipients |
| Q39312540 | Negative Cardiovascular Consequences of Small Molecule Immunosuppressants. |
| Q34377654 | Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients |
| Q64260637 | Non-immunological complications following kidney transplantation |
| Q38186327 | Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment |
| Q37335062 | Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. |
| Q89871308 | Post-Transplantation Diabetes Mellitus |
| Q38657521 | Post-transplantation diabetes-state of the art. |
| Q37779718 | Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk |
| Q37945873 | Prevention of cardiovascular disease in adult recipients of kidney transplants |
| Q93002346 | Ratio of triglyceride to high-density lipoprotein cholesterol and risk of major cardiovascular events in kidney transplant recipients |
| Q42343473 | Renal association clinical practice guideline in post-operative care in the kidney transplant recipient |
| Q37516861 | Renal transplantation in high cardiovascular risk patients |
| Q38242068 | Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis |
| Q91235170 | Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study |
| Q35108893 | Rosuvastatin in diabetic hemodialysis patients |
| Q35747445 | Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial |
| Q51173466 | Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs. |
| Q57750288 | Single Nucleotide Polymorphisms and Long-Term Clinical Outcome in Renal Transplant Patients: A Validation Study |
| Q33692765 | Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients |
| Q47106229 | Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation |
| Q36949237 | Statin use is associated with prolonged survival of renal transplant recipients. |
| Q34086279 | Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials |
| Q37986355 | Statins in the management of dyslipidemia associated with chronic kidney disease |
| Q34926989 | Survival in pediatric dialysis and transplant patients |
| Q34531972 | Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality |
| Q35137013 | The complex interplay between cholesterol and prostate malignancy |
| Q87610800 | The kidney and lipids: preface |
| Q42912193 | The lipid story in chronic kidney disease: a long story with a happy end? |
| Q34636135 | The safety of statins in clinical practice |
| Q57750538 | The use of fluvastatin in cardiovascular risk management |
| Q64239364 | Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014 |
| Q38250176 | mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? |
| Q38962103 | mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions |
Search more.